Limited clinical benefit from trastuzumab in recurrent endometrial cancer: Two case reports

Gynecologic and Obstetric Investigation

Volumn 67, Issue 1, 2009, Pages 46-48

  Vandenput, I ^a   Vanden Bempt, I ^a   Leunen, K ^a   Neven, P ^a   Berteloot, P ^a   Moerman, P ^a   Vergote, I ^a   Amant, F ^a,b,c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c RESEARCH FOUNDATION FLANDERS FWO   (Belgium)

Author keywords

Endometrial cancer; HER 2 neu; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TRASTUZUMAB;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CASE REPORT; DRUG EFFICACY; ENDOMETRIUM CANCER; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; LOADING DRUG DOSE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RECURRENT CANCER; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, ENDOMETRIOID; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, ERBB-2;

EID: 53249111894     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000161568     Document Type: Article

References (5)

1. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I: Endometrial cancer. Lancet 2005;366:491-505.
2. Vanden Bempt I, Vanhentenrijk V, Drijkoningen M, Wlodarska I, Vandenberghe P, De Wolf-Peeters C: Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas. Histopathology 2005;46:431-441.
3. Odicino F, Bignotti E, Rossi E, Pasinetti B, Tassi R, Donzelli C, Falchetti M, Fontana P, Grigolato P, Pecorelli S: HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization. Int J Gynecol Cancer 2008;18:14-21.
4. Villella JA, Cohen S, Smith DH, Hibshoosh H, Hershman D: HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. Int J Gynecol Cancer 2006;16:1897-1902.
5. Jewell E, Secord AA, Brotherton T, Berchuck A: Use of trastuzumab in the treatment of metastatic endometrial cancer. Int J Gynecol Cancer 2006;16:1370-1373.